You are here

Latest Stocks: The Shire PLC (SHP) Earns “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Shire PLC (LON:SHP) in a report issued on Monday.

SHP has been the topic of several other research reports. Deutsche Bank AG reaffirmed a buy rating on shares of Shire PLC in a report on Tuesday, January 3rd. Liberum Capital reaffirmed a buy rating and set a GBX 5,500 ($67.25) price target on shares of Shire PLC in a report on Thursday, December 22nd. Jefferies Group LLC reaffirmed a buy rating and set a GBX 6,600 ($80.69) price target on shares of Shire PLC in a report on Friday, February 17th. Citigroup Inc reaffirmed a buy rating on shares of Shire PLC in a report on Friday, February 17th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Shire PLC from GBX 6,300 ($77.03) to GBX 6,000 ($73.36) and set an overweight rating on the stock in a report on Wednesday, January 4th. One equities research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Shire PLC currently has an average rating of Buy and a consensus target price of GBX 6,115.60 ($74.77).

Shares of Shire PLC (LON:SHP) opened at 4830.50 on Monday. Shire PLC has a 12 month low of GBX 2,707.19 and a 12 month high of GBX 5,377.00. The stock’s market cap is GBX 43.60 billion. The firm’s 50-day moving average is GBX 4,713.18 and its 200 day moving average is GBX 4,767.70.

The firm also recently declared a dividend, which will be paid on Tuesday, April 25th. Investors of record on Thursday, March 9th will be given a GBX 20.64 ($0.25) dividend. This represents a yield of 0.43%. The ex-dividend date of this dividend is Thursday, March 9th. This is a boost from Shire PLC’s previous dividend of $3.51.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Related posts

Leave a Comment